Pregledni rad

COVID-19 and Antihypertensive Therapy

Jure Samardžić

Sažetak

Cardiovascular diseases (CVDs) are significantly prevalent in COVID-19 patients. According to all relevant reports and studies to date, CVDs are associated with a worse clinical course and higher mortality when combined with COVID-19. Arterial hypertension, as the most common cardiovascular entity and risk factor for premature mortality in the population, is of particular interest as a COVID-19 comorbidity due to insufficiently clarified association with COVID-19 outcomes, but also due to the potential harm of some antihypertensive drugs – specifically renin-angiotensin inhibitors, which are very often the drug of choice for treating hypertension. The presented data in this article, supported by the latest relevant literature and recommendations on the topic, will bring closer this issue and current approach to the treatment of arterial hypertension during the COVID-19 pandemic.

Ključne riječi

COVID-19; arterial hypertension; antihypertensive drugs

Hrčak ID:

244328

URI

https://hrcak.srce.hr/244328

Datum izdavanja:

30.9.2020.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.851 *